Compare Gilead Sciences, Inc. (GILD) vs Palantir Technologies Inc (PLTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Palantir Technologies Inc — how do they compare? Gilead Sciences, Inc. trades at $135.59 (market cap $163.51B), while Palantir Technologies Inc trades at $133.71 (market cap $320.66B). The key difference: Palantir Technologies Inc is the larger of the two by market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while Palantir Technologies Inc pays none. Which is the better fit depends on your goals.
| GILD | PLTR | |
|---|---|---|
Market Cap | $163.51B | $320.66B |
Sector | Health | Technology |
52-Week High | $155.80 | $207.18 |
52-Week Low | $108.22 | $107.27 |
Enterprise Value | $178.05B | $312.85B |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Palantir (PLTR) trades at $133.01, down 0.53% on the day, showing resilience near key support at $133 after recent volatility. The stock maintains a bullish technical trend with strong moving average signals, while fundamentals reveal explosive growth with 2025 revenue reaching $4.48 billion and net income surging to $1.63 billion. Recent partnerships with Nvidia and consistent earnings beats highlight ongoing business momentum, though valuation multiples remain elevated at 150x P/E and 66x P/S ratios.
The outlook remains positive given strong earnings trajectory and AI infrastructure demand, with analyst consensus target at $185.75 suggesting 40% upside potential. Primary risks include premium valuation sensitivity, competitive pressures in AI software, and execution challenges in sustaining high growth rates. Second quarter 2026 earnings on August 3 will be critical for validating current momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Palantir Technologies Inc
Palantir Technologies provides organizations with solutions to manage large disparate data sets in an attempt to gain insight and drive operational outcomes. Founded in 2003, Palantir released its Gotham software platform in 2008, which focuses on the government intelligence and defense sectors. Palantir expanded into various commercial markets with its Foundry software platform in 2016 with the intent of becoming the data operating system for companies and industries. The Denver company had 125 customers as of its initial public offering and roughly splits its revenue between commercial and government customers.
Read more on PLTR →
